Trials / Completed
CompletedNCT03152591
Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome
A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study was to evaluate whether LIK066 can be developed for the treatment of polycystic ovary syndrome (PCOS) in overweight and obese women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LIK066 | LIK066 tablets for oral administration |
| DRUG | Placebo | Placebo tablets matching LIK066 tablets, for oral administration |
Timeline
- Start date
- 2017-07-24
- Primary completion
- 2018-06-25
- Completion
- 2018-06-25
- First posted
- 2017-05-15
- Last updated
- 2021-01-05
- Results posted
- 2019-05-09
Locations
5 sites across 2 countries: United States, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03152591. Inclusion in this directory is not an endorsement.